Skip to content

Role of Adipose Tissue in Pathogenesis of Insulin Resistance

Role of Adipose Tissue in Pathogenesis of Insulin Resistance

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT00439491
Enrollment
35
Registered
2007-02-23
Start date
2004-01-31
Completion date
2006-12-31
Last updated
2007-02-23

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Obesity, Insulin Resistance

Keywords

Obesity, Insulin resistance, Hypocaloric diet, Adipose tissue, adipocytokine

Brief summary

The aim of the study was to investigate the relationship between insulin resistance and body composition in relation to secterion and expression of adipocytokines. Obese subjects undergo 6 months hypocaloric diet and, before, during and at the end of the diet, plasma samples and subcutaneous adipose tissue samples are obtained for subsequent analysis. In addition, body composition and insulin resistance are measured before and during the diet.

Detailed description

The aim of the study was to investigate the relationship between insulin resistance and body composition in relation to secterion and expression of adipocytokines. Obese subjects undergo 6 months hypocaloric diet without any medication and, before, during and at the end of the diet, plasma samples and subcutaneous adipose tissue samples are obtained for subsequent analysis. Adipose tissue samples are obtained using needle biopsy. In addition, before and during the diet,body composition is measured using multifrequency bioimpedance and insulin resistance is evaluated using either hyperinsulinemic clamp or glucose/insulin - derived indices.

Interventions

Sponsors

Charles University, Czech Republic
Lead SponsorOTHER

Study design

Allocation
NON_RANDOMIZED
Intervention model
SINGLE_GROUP
Primary purpose
PREVENTION
Masking
NONE

Eligibility

Sex/Gender
FEMALE
Age
18 Years to 60 Years
Healthy volunteers
No

Inclusion criteria

* Obesity

Exclusion criteria

* Diabetes * Coronary heart disease * Eating disorders * Medication of beta blockers * Medication of antiobesity drugs

Design outcomes

Primary

MeasureTime frame
Body fat
Body weight

Secondary

MeasureTime frame
Insulin resistance
Adipocytokine plasma levels
Adipocytokine adipose tissue expression

Countries

Czechia

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026